FOXO4-DRI: the peptide that talked old mice out of their worn-out cells

Cells that will not die and will not work

When a cell takes too much damage to repair, it has two honourable exits: die quietly, or shut down permanently. The second state is senescence. The cell stops dividing, which prevents it becoming a tumour, but it does not leave. It sits in the tissue leaking inflammatory signals, a mixture researchers call the senescence-associated secretory phenotype, or SASP ^[1].

Senescent cells build up with age. Mouse experiments from 2011 onwards showed that removing them genetically delays several age-related problems ^[4]. That raised an obvious question: could a drug clear them, and could it help animals that are already old and already frail?

FOXO4-DRI was the answer one group proposed, and it produced some of the most photogenic results in ageing research: bald mice growing their coats back.

Origin: finding the pact that keeps them alive

The Rotterdam team asked what keeps senescent cells alive when their damage should have triggered apoptosis. They identified FOXO4, a transcription factor that accumulates in senescent cells and holds p53, the cell's self-destruct supervisor, in the nucleus and out of action ^[1].

Then came the chemistry. Peptide researchers had shown that a protein's binding surface can sometimes be mimicked by a peptide built from D-amino acids in reverse order, a trick called D-retro-inverso ^[1]. Such peptides tend to resist breakdown and last longer in the body, and several had already been through clinical trials for other purposes ^[1].

So the team built the FOXO4 region as a D-retro-inverso peptide and fused it to HIV-TAT, a short, highly positive sequence that ferries cargo into cells. The result was FOXO4-DRI: the sequence H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH in all-D form, molecular weight 5358.2, made to better than 95% purity ^[1]. Using an antibody against the TAT tag, the peptide was detectable inside cells 2 to 4 hours after it was given and remained there for at least 72 hours ^[1].

How it works: separating two negotiators

Imagine a supervisor whose signature authorises a factory's demolition. In a senescent cell, FOXO4 keeps that supervisor in a side room, signing nothing. FOXO4-DRI is a decoy: it binds p53 more tightly than FOXO4 does, so the supervisor is released, leaves the nucleus and triggers the cell's own demolition ^[1].

Nuclear magnetic resonance experiments confirmed the competition directly, with FOXO4-DRI out-competing FOXO4 for p53 ^[1]. A 2025 structural study from the same collaboration mapped the interaction more precisely, showing that FOXO4-DRI binds a floppy, unstructured part of p53 and that the positively charged TAT portion also contributes to the grip ^[7].

Healthy cells have p53 too, which is why selectivity matters. In practice, senescent cells appear to depend on this arrangement in a way normal cells do not ^[1].

What the research shows

In cell culture

In human IMR90 fibroblasts made senescent by radiation, FOXO4-DRI reduced viability of senescent cells about 11.73 times more readily than control cells ^[1]. The effect appeared 24 to 36 hours after treatment. The same peptide built from ordinary L-amino acids did not work, nor did an unrelated control peptide ^[1]. Notably, the peptide was more potent against senescent cells whose inflammatory output was high, which suggests it hits the cells doing the most damage ^[1].

In fast-ageing mice

The team used XpdTTD/TTD mice, which carry a DNA-repair defect and age quickly. These mice lose their fur, and treatment produced a clear improvement in fur density, confirmed by measuring abdominal skin temperature, which is abnormally high in bald mice ^[1].

Activity told a similar story. Fast-ageing mice ran 1.37 ± 0.54 km per day on a cage wheel, against 9.37 ± 1.1 km for normal mice. FOXO4-DRI increased wheel running over time in most of the treated animals ^[1].

The kidney gave the clearest numbers. Plasma urea rises when filtering declines, and it was high in these mice. Treatment normalised plasma urea, restored the senescence marker LMNB1 in kidney tubules and reduced the inflammatory signal IL-6 there ^[1].

In naturally aged mice

Normal old mice are messier to study, because senescence varies a lot between animals, and the variation in wheel running was too large to use ^[1]. Even so, FOXO4-DRI reduced a genetic marker of senescence, improved fur density and responsiveness, and lowered both plasma urea and creatinine, two independent measures of kidney filtering ^[1].

Press coverage at the time described fur regrowing after about 10 days, and treated old mice running roughly twice as far after about three weeks ^[2].

Safety signals in the mouse work

One existing class of senolytics, the BCL-2 family inhibitors, causes a drop in platelets. FOXO4-DRI did not noticeably change platelet levels or other blood values, and the mice were treated three times a week for more than ten months without obvious side effects ^[1,2].

Follow-up studies

Other groups have used the peptide as a tool. In aged mice, it was reported to target senescent Leydig cells in the testis and to improve age-related testosterone decline ^[5], and a 2024 study reported better sperm production ^[6]. A separate team used molecular modelling to design related peptides, one of which reduced senescent cells in the livers of older mice and, combined with a targeted drug, improved survival in mouse melanoma models ^[8].

Senolytics: the wider field

FOXO4-DRI belongs to a family of experimental compounds that aim to clear senescent cells rather than to slow their creation.

The dasatinib and quercetin combination was the first senolytic pair identified, in 2015 ^[3]. Its 2019 pilot in idiopathic pulmonary fibrosis enrolled 14 people with no control group and was designed to test feasibility, not benefit ^[11]. UBX0101 is the field's clearest disappointment: no dose beat placebo on knee pain at 12 weeks, and the company dropped the programme ^[14]. Fisetin's story is a caution about mouse data too: it extended lifespan in one laboratory ^[12] and did not do so in a large multi-site programme that tests candidate drugs under standardised conditions ^[13].

What we don't know yet

• No human data. We found no published clinical trial of FOXO4-DRI. The 2017 authors themselves wrote that more research was needed to assess translational potential, and whether removing such cells is even safe ^[1].
• Lifespan. The mouse work measured health markers, not how long the animals lived ^[1].
• The p53 problem. p53 is a tumour suppressor, and a compound that redirects it has to be judged carefully for cancer risk in both directions.
• Dose and delivery. The mouse studies used repeated injections over months, and nothing is known about human pharmacokinetics ^[1].
• Where the company went. Cleara Biotech, founded in 2018 around this work, selected two later peptides, CL04177 and CL04183, as leads ^[9]. By 2026 it described CL04183 as a first-in-class peptide for cancers with impaired p53, with toxicology complete and a first human trial planned for 2027 ^[10]. That is a different molecule and a different target from the original ageing story.
• Field-level uncertainty. Senolytics as a class have not yet produced a positive phase 3 result in any disease ^[11,14].

Regulatory status

• Medicine status: FOXO4-DRI is not approved as a medicine anywhere, and we found no clinical trial registration for it.
• WADA: We found no mention of FOXO4-DRI on the WADA Prohibited List; peptides with no clinical use may still fall under broader prohibited categories.
• Company programmes: Cleara Biotech holds US and Chinese patents covering its all-D cell-penetrating peptides, including CL04183, with protection stated to 2041, and says the compound is ready for regulatory filing ^[10].
• Other senolytics: No senolytic is approved for ageing or for any age-related disease. Dasatinib is approved as a leukaemia drug, which is a different use entirely ^[3,11].

In the lab: handling and storage

FOXO4-DRI is supplied as a lyophilised powder, often as a trifluoroacetate salt from purification. The original work stored it at −20 °C in 1 mg single-use portions specifically to avoid freeze-thaw artefacts, and that remains good practice ^[1]. Protect it from light and moisture, and let vials reach room temperature before opening so that water does not condense on the powder. Its arginine-rich TAT segment gives it a strong positive charge and makes it highly water-soluble; the original study dissolved it in phosphate-buffered saline ^[1]. Being an all-D peptide, it resists protease breakdown far better than its natural counterpart, but that says nothing about stability in a vial. Our guides on storing research peptides and reading a certificate of analysis go further, and the FOXO4-DRI product page lists the lot specifications.

FAQ